TP53 and sarcoma: Our results are also in line with the hypothesis [63] that TP53 mutations are early events and selected for in ectodermal and mesodermal-derived tumors, such as sarcomas, in contrast to tumors from endodermal origin, such as colon cancer, in which TP53 mutations are the last to occur.